{"entity":{"id":"nct06966700","kind":"trial","name":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","aka":[],"tldr":"A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Carboplatin, Doxorubicin, Epirubicin and Cyclophosphamide in triple-negative breast cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032). ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 2400 participants. Primary completion is estimated at 2033-03-23. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib. Registered primary measures: Percentage of Participants with Pathological Complete Response (pCR) at the Time of Definitive Surgery; Event-Free Survival (EFS).","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06966700","url":"https://clinicaltrials.gov/study/NCT06966700"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc","tnbc-early"],"sections":[],"technologies":["adc","checkpoint-inhibitor","cytotoxic-chemotherapy","platinum","topoisomerase-inhibitors"],"targets":["trop2"],"drugs":["sacituzumab-tirumotecan","pembrolizumab","carboplatin","doxorubicin","epirubicin","cyclophosphamide"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-10-06: recruiting. Enrollment is planned at 2400 participants. Primary completion is estimated at 2033-03-23. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT06966700","phase":"3","setting":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06966700","source":"https://clinicaltrials.gov/study/NCT06966700","fetchedAt":"2026-10-07T16:55:19.231Z","studySha256":"3a7608e91d5db72388a9018b434d1c52504f554bb43cfa48b07742da699360a7","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-06","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":2400,"enrolmentType":"ESTIMATED","siteCount":326,"recruitingSiteCount":323,"countries":["Argentina","Australia","Belgium","Brazil","Canada","Chile","China","Colombia","Czechia","Finland","France","Germany","Greece","Guatemala","Hong Kong","Hungary","India","Israel","Italy","Japan","Malaysia","New Zealand","Norway","Peru","Philippines","Poland","Portugal","Romania","Singapore","South Africa","South Korea","Spain","Sweden","Taiwan","Thailand","Turkey (Türkiye)","Ukraine","United Kingdom","United States","Vietnam"]}],"started":"2025-06-30","startedType":"actual","enrolled":2400,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06966700/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"topoisomerase-inhibitors","kind":"technology","name":"Topoisomerase-I inhibitors (and ADC payloads)","route":"/technologies/topoisomerase-inhibitors/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"epirubicin","kind":"drug","name":"Epirubicin","route":"/drugs/epirubicin/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"sacituzumab-tirumotecan","kind":"drug","name":"Sacituzumab tirumotecan","route":"/drugs/sacituzumab-tirumotecan/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}